Skip to main content
    B

    Boston Scientific Corp (BSX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $43.70
    -0.64 (-1.44%)

    Market Cap: $64.27B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Boston Scientific Corp (BSX) Earnings: Report Dates and Results

    Updated Oct 28, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Boston Scientific (BSX) is expected to report earnings on Feb 2, 2027. In the quarter ended Sep 30, 2026, Boston Scientific reported EPS of $0.73, in line with the $0.73 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    75%(30/40)
    Avg Surprise
    +16.81%

    Upcoming Estimates

    Reports Feb 2, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.78
    Range$0.74 - $0.83
    26 analysts
    Revenue Consensus
    $5.23B
    Range$5.04B - $5.51B
    26 analysts
    Reports Apr 20, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.74
    Range$0.70 - $0.78
    16 analysts
    EPS Revisions
    0
    10
    30d
    EPS Estimate DriftChange to current
    90d ago$0.80-7.2%
    60d ago$0.80-7.2%
    30d ago$0.80-6.9%
    7d ago$0.80-6.9%
    Current$0.74
    Revenue Consensus
    $5.06B
    Range$4.94B - $5.14B
    15 analysts

    Next Report

    BSX has an expected report date of Feb 2, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 2.5% below the $0.80 reported for the quarter ended Dec 31, 2025.

    BSX Earnings Call

    The latest BSX earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, BSX beat 30, missed 6 and matched 4. Revenue for the quarter ended Sep 30, 2026 was $5.14B, up 1.4% from $5.07B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.73$0.73$0.58 - $0.820.00%In line-2.7%240 up, 11 downOct 28, 2026$5.14B
    Jun 30, 2026$0.86$0.83$0.81 - $0.84+3.61%Beat+14.7%230 up, 10 downJul 29, 2026$5.44B
    Mar 31, 2026$0.80$0.79$0.77 - $0.83+1.27%Beat+6.7%262 up, 4 downApr 22, 2026$5.20B
    Dec 31, 2025$0.80$0.78$0.77 - $0.81+2.56%Beat+14.3%271 up, 0 downFeb 4, 2026$5.29B
    Sep 30, 2025$0.75$0.71$0.70 - $0.76+5.63%Beat+19.0%262 up, 3 downOct 22, 2025$5.07B
    Jun 30, 2025$0.75$0.73$0.71 - $0.75+2.74%Beat+21.0%253 up, 0 downJul 23, 2025$5.06B
    Mar 31, 2025$0.75$0.67$0.66 - $0.70+11.94%Beat+33.9%262 up, 0 downApr 23, 2025$4.66B
    Dec 31, 2024$0.70$0.66$0.64 - $0.68+6.06%Beat+27.3%264 up, 2 downFeb 5, 2025$4.56B
    Sep 30, 2024$0.63$0.59$0.57 - $0.62+6.78%Beat+26.0%270 up, 0 downOct 23, 2024$4.21B
    Jun 30, 2024$0.62$0.58$0.57 - $0.59+6.90%Beat+17.0%271 up, 0 downJul 24, 2024$4.12B
    Mar 31, 2024$0.56$0.51$0.50 - $0.52+9.80%Beat+19.1%262 up, 1 downApr 24, 2024$3.86B
    Dec 31, 2023$0.55$0.51$0.50 - $0.52+7.84%Beat+22.2%261 up, 0 downJan 31, 2024$3.73B
    Sep 30, 2023$0.50$0.48$0.47 - $0.49+4.17%Beat+16.3%260 up, 0 downOct 26, 2023$3.53B
    Jun 30, 2023$0.53$0.49$0.48 - $0.50+8.16%Beat+20.5%270 up, 0 downJul 27, 2023$3.60B
    Mar 31, 2023$0.47$0.43$0.42 - $0.45+9.30%Beat+20.5%241 up, 0 downApr 26, 2023$3.39B
    Dec 31, 2022$0.45$0.47$0.45 - $0.50-4.26%Miss0.0%223 up, 0 downFeb 1, 2023$3.24B
    Sep 30, 2022$0.43$0.44$0.42 - $0.46-2.27%Miss+4.9%241 up, 1 downOct 26, 2022$3.17B
    Jun 30, 2022$0.44$0.42$0.41 - $0.44+4.76%Beat+10.0%231 up, 1 downJul 27, 2022$3.24B
    Mar 31, 2022$0.39$0.39$0.37 - $0.400.00%In line+5.4%241 up, 1 downApr 27, 2022$3.03B
    Dec 31, 2021$0.45$0.44$0.43 - $0.47+2.27%Beat+95.7%24N/AFeb 2, 2022$3.13B
    Sep 30, 2021$0.41$0.40$0.38 - $0.41+2.50%Beat+10.8%260 up, 1 downOct 27, 2021$2.93B
    Jun 30, 2021$0.40$0.37$0.36 - $0.38+8.11%Beat+400.0%27N/AJul 27, 2021$3.08B
    Mar 31, 2021$0.37$0.31$0.28 - $0.32+19.35%Beat+32.1%26N/AApr 28, 2021$2.75B
    Dec 31, 2020$0.23$0.31$0.26 - $0.37-25.81%Miss-50.0%25N/AFeb 3, 2021$2.71B
    Sep 30, 2020$0.37$0.25$0.12 - $0.32+48.00%Beat-5.1%24N/AOct 28, 2020$2.66B
    Jun 30, 2020$0.08-$0.02-$0.22 - $0.25+500.00%Beat-79.5%22N/AJul 29, 2020$2.00B
    Mar 31, 2020$0.28$0.32$0.26 - $0.36-12.50%Miss-20.0%14N/AApr 29, 2020$2.54B
    Dec 31, 2019$0.46$0.44$0.43 - $0.45+4.55%Beat+17.9%21N/AFeb 5, 2020$2.90B
    Sep 30, 2019$0.39$0.38$0.36 - $0.40+2.63%Beat+11.4%22N/AOct 23, 2019$2.71B
    Jun 30, 2019$0.39$0.38$0.37 - $0.39+2.63%Beat-4.9%22N/AJul 24, 2019$2.63B
    Mar 31, 2019$0.35$0.36$0.33 - $0.36-2.78%Miss+6.1%23N/AApr 24, 2019$2.49B
    Dec 31, 2018$0.39$0.36$0.32 - $0.38+8.33%Beat+14.7%19N/AFeb 6, 2019$2.56B
    Sep 30, 2018$0.35$0.34$0.33 - $0.35+2.94%Beat+12.9%24N/AOct 24, 2018$2.39B
    Jun 30, 2018$0.41$0.34$0.34 - $0.35+20.59%Beat+28.1%23N/AJul 25, 2018$2.49B
    Mar 31, 2018$0.33$0.32$0.31 - $0.33+3.13%Beat+13.8%23N/AApr 25, 2018$2.38B
    Dec 31, 2017$0.34$0.34$0.32 - $0.360.00%In line+13.3%22N/AFeb 1, 2018$2.41B
    Sep 30, 2017$0.31$0.31$0.28 - $0.320.00%In line+14.8%23N/AOct 26, 2017$2.22B
    Jun 30, 2017$0.32$0.31$0.30 - $0.32+3.23%Beat+18.5%24N/AJul 27, 2017$2.26B
    Mar 31, 2017$0.29$0.30N/A-3.33%Miss+3.6%N/AN/AApr 27, 2017$2.16B
    Dec 31, 2016$0.30$0.29N/A+3.45%Beat+15.4%N/AN/AFeb 2, 2017$2.19B
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $3.05, up 21.5% from the year before. It was $1.12 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$3.05+21.5%
    Dec 31, 2024$2.51+22.4%
    Dec 31, 2023$2.05+19.9%
    Dec 31, 2022$1.71+4.9%
    Dec 31, 2021$1.63+69.8%
    Dec 31, 2020$0.96-39.6%
    Dec 31, 2019$1.59+7.4%
    Dec 31, 2018$1.48+17.5%
    Dec 31, 2017$1.26+12.5%
    Dec 31, 2016$1.12N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,900 words across 16 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,90716
    2026Q2Jun 30, 20267,23415
    2026Q1Mar 31, 20266,96516
    2025Q4Dec 31, 20257,62018
    2025Q3Sep 30, 20258,00917
    2025Q2Jun 30, 20257,73514
    2025Q1Mar 31, 20258,07517
    2024Q4Dec 31, 20248,45219

    2026Q3 Earnings Call

    Opening remarks

    Lauren Tengler Vice President, Investor Relations Thank you, Drew, and thanks to everyone for joining us. With me today are Mike Mahoney, Chairman and Chief Executive Officer, and John Monson, Executive Vice President and Chief Financial Officer. During the Q&A session, Mike and John will be joined by Joe Fitzgerald, Executive Vice President and Group President, Cardiology, and our Chief Medical Officer, Dr. Ken Stein. We issued a press release earlier this morning announcing our Q3 2026 results, which included reconciliations of the non-GAAP measures used in this release. The release, as well as reconciliations of the non-GAAP measures used in today's call, can be found on the Investor Relations section of our website. Please note that on the call, operational revenue excludes the impact of foreign currency fluctuations, and organic revenue further excludes certain acquisitions and divestitures for which there are less than a full period of comparable net sales. Guidance excludes our previously announced agreement to acquire Penumbra, which we expect to close in early 2027. For more information, please refer to the Q3 financial and operating highlights deck, which may be found on the Investor Relations section of our website. On this call, all references to sales and revenue are organic, and relative growth is compared to the same quarter of the prior year unless otherwise specified. This call contains forward-looking statements regarding, among other things, our financial performance, business plans, market expectations, and product performance and development. These statements are based on our current beliefs using information available to us as of today's date and are not intended to be guarantees of future events or performance. If our underlying assumptions turn out to be incorrect or certain risks or uncertainties materialize, actual results could vary materially from those projected by the forward-looking statements. Factors that may cause such differences are discussed in the earnings release we issued earlier this morning and our periodic reports and other filings with the SEC, including the Risk Factors section of our most recent annual report on Form 10-K. Boston Scientific disclaims any intention or obligation to update these forward-looking statements except as required by law. In addition, this call does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval in connection with the proposed transaction with Penumbra. Boston Scientific has filed with the SEC a registration statement on Form S-4 containing a proxy statement of Penumbra and a prospectus of Boston Scientific that contains important information about Penumbra, Boston Scientific, the proposed transaction, and related matters. At this point, I will turn it over to Mike.

    Michael F. Mahoney Chairman and CEO Thanks, Lauren. Thank you to everyone for joining us today.

    Frequently Asked Questions About BSX

    When is Boston Scientific's next earnings date?

    Boston Scientific's next earnings report is expected for Feb 2, 2027.

    Did BSX beat earnings estimates last quarter?

    Boston Scientific reported EPS of $0.73 for the quarter ended Sep 30, 2026, in line with the $0.73 estimate.

    What EPS do analysts expect from BSX next quarter?

    The consensus EPS estimate for Boston Scientific for the quarter ending Dec 31, 2026 is $0.78 from 26 analysts, with estimates from $0.74 to $0.83.

    How often does BSX beat earnings estimates?

    Boston Scientific beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +4.23%.